General Genomics

Industry: Therapeutics for gout

General Genomics engineers biomolecules with valuable applications. The company’s initial product is a novel uricase enzyme designed to treat gout and tumor lysis syndrome.
This enzyme and treatment meet an important need, because many of the currently available gout treatments pose a risk of allergic reactions that can potentially be lethal. Gout rates have been soaring globally and are expected to rise to 39 million by 2019.
In the long term, General Genomics plans to apply its engineering platform to create proteins that are of use in a variety of industrial markets, including detergents, biofuels, and food and beverage processing.

Company website: General Genomics

Back to companies